On February 9, Bristol-Myers Squibb (BMS; Princeton, NJ) reported that it had altered its 1995 agreement with Entremed (Rockville, MD) and returned the anti-angiogenesis compound, angiostatin, to Entremed for further development. BMS had trouble consistently producing reliable potency results for angiostatin in mammalian cells. "There's no question of the efficacy of the protein," maintains Mary Sundeen, Entremed spokesperson, "it's just a matter of reliably reproducing [angiostatin] in that [mammalian] cell line." Although BMS retains the right to reenter the agreement once the safety and efficacy of angiostatin have been proven in humans, the news caused Entremed's share price to plummet almost 50%. However, Entremed stock bounced back following reports a day later that researchers from the National Cancer Institute (NCI; Bethesda, MD) had verified Judah Folkman's (Children's Hospital and Harvard Medical School, Boston, MA) anticancer work on endostatin—a relative of angiostatin also licensed by Entremed. Folkman's 1997 research had indicated both endostatin and angiostatin to be effective anticancer agents in mice. The NCI is planning a phase I trial of endostatin.